Document:

Document

Exhibit 10.10

LICENSE AGREEMENT
This License Agreement (this “Agreement”) is entered into as of this 16th day of January, 2018 (the “Effective Date”), by and between Kronos Bio, Inc., a corporation existing under the laws of Delaware, having a place of business at 689 5th Avenue, 12th Floor, New York, NY 10022 (“Licensee”) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
WHEREAS, the technology claimed in the Patent Rights (as defined below) was developed in research conducted by Dr. Stuart Schreiber, an employee of the Howard Hughes Medical Institute (“HHMI”) and faculty member at Harvard at the time, together with other researchers at Harvard;
WHEREAS, researcher Dr. Kristopher Depew was also an employee of HHMI at the time such technology was developed;
WHEREAS, Drs. Schreiber and Depew have assigned to HHMI their interests in the Patent Rights, and HHMI has assigned to Harvard its rights in the Patent Rights, subject to certain rights retained by HHMI as specifically described below;
WHEREAS, Licensee wishes to obtain a license under the Patent Rights;
WHEREAS, Harvard desires to have products based on the inventions described in the Patent Rights developed and commercialized to benefit the public; and
WHEREAS, Licensee has represented to Harvard, in order to induce Harvard to enter into this Agreement, that Licensee shall commit itself to commercially reasonable efforts to develop, obtain regulatory approval for and commercialize such products;
NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:
1.Definitions.
Whenever used in this Agreement with an initial capital letter, the terms defined in this Article 1, whether used in the singular or the plural, shall have the meanings specified below.
1.1.“Affiliate” means, with respect to a person, organization or entity, any person, organization or entity controlling, controlled by or under common control with, such person, organization or entity.   For purposes of this definition only, “control” of another person, organization or entity will mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, control will be presumed to exist when a person, organization or entity (a) owns or directly controls fifty percent (50%) or more of the outstanding voting stock or other 
1

ownership interest of the other organization or entity or (b) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the other organization or entity. The parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such cases such lower percentage will be substituted in the preceding sentence.
1.2.“Licensed  Product”  means  on  a  country-by-country  basis,  any  product,  the making, using, selling, offering for sale, importing or exporting in the country in question would (without the license granted hereunder) infringe directly, indirectly by inducement of infringement, or indirectly by contributory infringement, at least one Valid Claim in that country.
1.3.“Licensed Service” means any process, method or service, (a) the performance, sale or offer for sale of which process, method or service, or part thereof, would infringe (without the license granted hereunder) at least one Valid Claim in that country or (b) uses a Licensed Product.
1.4.“Patent Rights” means:  (a) the patents and patent applications listed in Exhibit 1.4; (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent application identified in (a); (c) any patents issuing on any patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof;  (d) any claim of a continuation-in- part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any patents and patent applications identified in (a) through (e).
1.5.“Valid Claim” means: (a) a claim of an issued and unexpired patent within the Patent Rights that has not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (ii) rendered unenforceable through disclaimer or otherwise, (iii) abandoned or (iv) permanently lost through an interference or opposition proceeding without any right of appeal or review; or (b) a pending claim of a pending patent application within the Patent Rights that (i) has been asserted and continues to be prosecuted in good faith and (ii) has not been abandoned or finally rejected without the possibility of appeal or refilling.
2.License Grant.
2.1.License.  Subject to the terms and conditions set forth in this Agreement, Harvard hereby grants to Licensee a non-exclusive, worldwide, non-transferable, consideration-bearing 
2

license to its interest in the Patent Rights solely to develop, make, have made, use, market, offer for sale, sell and import Licensed Products and to perform Licensed Services.
2.2.HHMI.  HHMI has a fully paid-up, non-exclusive, irrevocable, worldwide license to exercise any intellectual property rights with respect to the Patent Rights for research purposes, with the right to sublicense to non-profit and governmental entities (the “HHMI License”).  Any and all licenses and other rights granted under this Agreement are explicitly made subject to the HHMI License.
2.3.Affiliates.  The licenses granted to Licensee under Section 2.1 shall include the right to have some or all of Licensee’s rights or obligations under this Agreement exercised or performed by one or more of Licensee’s Affiliates; provided that:
2.3.1.no such Affiliate shall be entitled to grant, directly or indirectly, to any third party any right of whatever nature under, or with respect to, or permitting any use or exploitation of, any of the Patent Rights, including any right to develop, manufacture, market or sell Licensed Products or perform Licensed Services; and
2.3.2.any act or omission taken or made by an Affiliate of Licensee under this Agreement shall be deemed an act or omission by Licensee under this Agreement.
2.4.No Other Grant of Rights.   Except as expressly provided in this Agreement, nothing in this Agreement shall be construed to confer any ownership interest, license or other rights upon Licensee by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of Harvard or any other entity, regardless of whether such technology, intellectual property rights, products or biological materials are dominant, subordinate or otherwise related to any Patent Rights.
3.Development and Commercialization.
3.1.Diligence. Licensee shall use commercially reasonable efforts to develop Licensed Products and Licensed Services and/or to introduce Licensed Products and Licensed Services into the commercial market or to utilize the Patent Rights for its own internal research and development programs.
3.2.Reporting.  Within sixty (60) days after the end of each calendar year, Licensee shall furnish Harvard with a written report summarizing its and its Affiliates’ efforts during the prior year to develop and commercialize Licensed Products and/or Licensed Services, including without limitation: (a) research and development activities; and (b) commercialization efforts. Each report shall contain a sufficient level of detail for Harvard to assess whether Licensee is in compliance with its obligations under Section 3.1 and a discussion of intended efforts for the then current year.
3

4.Consideration for Grant of License.
4.1.License Issuance Fee.  Licensee agrees to pay Harvard a non-refundable license fee of Ten Thousand U.S. Dollars ($10,000), due and payable within thirty (30) days after the Effective Date.
4.2.Annual License Maintenance Fee. Licensee agrees to pay Harvard annual license maintenance fees as follows:
4.2.1.Twenty Thousand U.S. Dollars ($20,000) due and payable within thirty (30) days after the first anniversary of the Effective Date;
4.2.2.Twenty Thousand U.S. Dollars ($20,000) due and payable within thirty (30) days after the second anniversary of the Effective Date; and
4.2.3.Twenty Five Thousand U.S. Dollars ($25,000) due and payable within thirty (30) days after the third and each subsequent anniversary of the Effective Date during the Term.
5.Payments.
5.1.Payment Currency.  All payments due under this Agreement will be paid in U.S. Dollars. Conversion of foreign currency to U.S. Dollars will be made at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the applicable Calendar Quarter.  Such payments will be without deduction of exchange, collection, or other charges.
5.2.Late Payments.  Any payments by Licensee that are not paid on or before the date such payments are due under this Agreement will bear interest at the lower of (a) one and one half percent (1.5%) per month and (b) the maximum rate allowed by law. Interest will accrue beginning on the first day following the due date for payment and will be compounded quarterly.  Payment of such interest by Licensee will not limit, in any way, Harvard’s right to exercise any other remedies Harvard may have as a consequence of the lateness of any payment.
5.3.Payment Method.  Each payment due to Harvard under this Agreement shall be paid by check or wire transfer of funds to Harvard’s account in accordance with written instructions provided by Harvard.  If made by wire transfer, such payments shall be marked so as to refer to this Agreement.
5.4.Withholding and Similar Taxes.  All amounts to be paid to Harvard pursuant to this Agreement shall be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes.
4

6.Intellectual Property.
6.1.Responsibility.  Harvard shall have sole responsibility for and control over the preparation, filing, prosecution, protection and maintenance of all Patent Rights, and all decision- making authority with regard to Patent Rights shall vest in Harvard (including, without limitation, as to whether to maintain or abandon any patent, patent application or claim thereof within Patent Rights).  Harvard shall keep Licensee informed with respect to the course and conduct of patent applications and prosecution matters.
6.2.Enforcement.  Harvard  shall  have  the right,  acting in  its  sole  discretion,  to prosecute in its own name and at its own expense any possible or actual infringement of patents related to the Patent Rights.  Licensee agrees to notify Harvard of each suspected or confirmed infringement of such patents of which it is or becomes aware.   Licensee agrees to reasonably cooperate in any action under this Section 6.2, provided that Harvard will reimburse Licensee for all reasonable costs and expenses incurred by Licensee in connection with providing such assistance.
6.3.Marking.  Licensee and its Affiliates shall mark all Licensed Products sold or otherwise disposed of by it in the United States with the word “Patent” and the number of all patents included within the Patent Rights that cover such Licensed Products.   All Licensed Products shipped or sold in other countries shall be marked in such a manner as to conform with the patent laws and practice of the country to which such products are shipped or in which such products are sold.
7.Warranties; Limitation of Liability.
7.1.Compliance with Law.  Licensee represents and warrants that it will comply, and will ensure that its Affiliates comply, with all local, state, federal and international laws and regulations relating to the development, manufacture, use, sale and importation of Licensed Products and the performance of Licensed Services.  Without limiting the foregoing, Licensee represents and warrants that it will comply, and will ensure that its Affiliates comply, with all United States export control laws and regulations  controlling the export of certain commodities and technical data, including without limitation all Export Administration Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and technical data to specified countries. Licensee hereby gives written assurance that it will comply with all United States export control laws and regulations, that it bears sole responsibility for its violation of any such laws and regulations, and that it will indemnify, defend, and hold Harvard and HHMI harmless  (in accordance with Section 8.1) for the consequences of any such violation.
7.2.No Warranty.
7.2.1.NOTHING CONTAINED HEREIN  SHALL BE DEEMED  TO  BE A WARRANTY BY HARVARD THAT IT CAN OR WILL BE ABLE TO OBTAIN PATENTS ON PATENT APPLICATIONS INCLUDED IN THE PATENT RIGHTS, OR THAT ANY OF 
5

THE PATENT RIGHTS WILL AFFORD ADEQUATE OR COMMERCIALLY WORTHWHILE PROTECTION.
7.2.2.HARVARD MAKES NO WARRANTIES WHATSOEVER AS TO THE COMMERCIAL OR SCIENTIFIC VALUE OF THE PATENT RIGHTS. HARVARD MAKES NO REPRESENTATION THAT THE PRACTICE OF THE PATENT RIGHTS OR THE DEVELOPMENT, MANUFACTURE, USE, SALE OR IMPORTATION OF ANY LICENSED PRODUCT OR THE PERFORMANCE OF LICENSED SERVICES, OR ANY ELEMENT THEREOF, WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS.
7.2.3.EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, PATENTS, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.
7.3.Limitation of Liability.
7.3.1.Except with respect to matters for which Licensee is obligated to indemnify Harvard under Article 8, neither party will be liable to the other with respect to any subject matter of this Agreement under any contract, negligence, strict liability or other legal or equitable theory for (a) any indirect, incidental, consequential or punitive damages or lost profits or (b) cost of procurement of substitute goods, technology or services.
7.3.2.Harvard’s aggregate liability for all damages of any kind arising out of or relating to this Agreement or its subject matter under any contract, negligence, strict liability or other legal or equitable theory shall not exceed the amounts paid to Harvard under this Agreement.
8.Indemnification and Insurance.
8.1.Indemnity.
8.1.1.Licensee shall indemnify, defend and hold harmless Harvard and its current and former directors, governing board members, trustees, officers, faculty, medical and professional staff, employees, students and agents and their respective successors, heirs and assigns (the “Indemnitees”) from and against any claim, liability, cost, expense, damage, deficiency, loss or obligation of any kind or nature (including reasonable attorneys’ fees and other costs and expenses of litigation) based upon, arising out of or otherwise relating to this Agreement, including any cause of action relating to product liability concerning any product, process or service made, used, sold or performed pursuant to any right or license granted under this Agreement (collectively “Claims”).  Neither Licensee nor Harvard shall settle any Claim without the prior written consent of the other, which consent shall not be unreasonably withheld. Licensee shall, at its own expense, provide attorneys reasonably acceptable to Harvard to defend 
6

against any actions brought or filed against any Indemnitee hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought.
8.1.2.HHMI, and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”), will be indemnified, defended by counsel acceptable to HHMI (such acceptance not to be unreasonably withheld), and held harmless by Licensee from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “HHMI Claims”), based upon, arising out of, or otherwise relating to this Agreement or any sublicense, including without limitation any cause of action relating to product liability. The previous sentence will not apply to any HHMI Claim to the extent that it is determined with finality by a court  of competent  jurisdiction  to result  from  the gross  negligence or willful misconduct of an HHMI Indemnitee. Notwithstanding any other provision of this Agreement, Licensee’s obligation to defend, indemnify and hold harmless the HHMI Indemnitees under this paragraph will not be subject to any limitation or exclusion of liability or damages or otherwise limited in any way.  The provisions of this Article 8 will survive termination of this Agreement. In the case of an HHMI Indemnitee, notice shall be given reasonably promptly following actual receipt of written notice of an HHMI Claim by an officer or attorney of HHMI.  Notwithstanding the foregoing, the delay or failure of an HHMI Indemnitee to give prompt notice to Licensee of any HHMI Claims shall not affect the rights of such HHMI Indemnitee unless, and then only to the extent that, such delay or failure is prejudicial to or otherwise adversely affects Licensee. The HHMI Indemnitees shall (i) permit Licensee, at its sole expense, to control the defense (including litigation and/or settlement) of the HHMI Claims, and (iii) reasonably cooperate with Licensee in the defense of such HHMI Claims, at the Licensee’s expense; provided, however, Licensee agrees not to settle any HHMI Claim against an HHMI Indemnitee without HHMI’s written consent, where (a) such settlement would include any admission of liability on the part of any HHMI Indemnitee, (b) such settlement would impose any restriction on any HHMI Indemnitee’s conduct of any of its activities, or (c) such settlement would not include an unconditional release of all HHMI Indemnitees from all liability for claims that are the subject matter of the settled HHMI Claim. The Licensee will keep HHMI informed of its defense of any HHMI Claims pursuant to this Section 8.1.2 (Indemnity).
8.2.Insurance.
8.2.1.Beginning at the time any Licensed Product is being commercially distributed or sold or any Licensed Service is being performed (other than for the purpose of obtaining regulatory approvals) by Licensee, or by an Affiliate or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $2,000,000 per incident and $3,000,000 annual aggregate and naming the Indemnitees and HHMI Indemnitees as additional insureds.  During clinical trials of any such Licensed Product, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in such equal or lesser amount as Harvard shall require, naming the Indemnitees and HHMI Indemnitees as additional insureds. Such commercial general liability 
7

insurance shall provide (a) product liability coverage and (b) broad form contractual liability coverage for Licensee’s indemnification obligations under this Agreement.
8.2.2.If Licensee elects to self-insure all or part of the limits described above in Section 8.2.1 (including deductibles or retentions that are in excess of $250,000 annual aggregate) such self-insurance program must be acceptable to Harvard and CRICO/RMF (Harvard’s insurer) in their sole discretion.   The minimum amounts of insurance coverage required shall not be construed to create a limit of Licensee’s liability with respect to its indemnification obligations under this Agreement.
8.2.3.Licensee shall provide Harvard with written evidence of such insurance upon request of Harvard.  Licensee shall provide Harvard with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance. If Licensee does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, Harvard shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods.
8.2.4.Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (a) the period that any Licensed Product is being commercially distributed or sold or any Licensed Service is being performed by Licensee or an Affiliate or agent of Licensee and (b) a reasonable period after the period referred to in (a) above, which in no event shall be less than fifteen (15) years.
9.Term and Termination.
9.1.Term.  The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article 9, shall continue in full force and effect until the expiration of the last to expire Valid Claim (the “Term”).
9.2.Termination.
9.2.1.Termination Without Cause.  Licensee may terminate this Agreement upon sixty (60) days prior written notice to Harvard.
9.2.2.Termination for Default.
9.2.2.1.In the event that either party commits a material breach of its obligations under this Agreement and fails to cure that breach within thirty (30) days after receiving written notice thereof, the other party may terminate this Agreement immediately upon written notice to the party in breach.
9.2.2.2.If Licensee defaults in its obligations under Section 8.2 to procure and maintain insurance or, if Licensee has in any event failed to comply with the notice requirements contained therein, then Harvard may terminate this Agreement immediately without notice or additional waiting period.
8

9.2.3.Bankruptcy.  Harvard may terminate this Agreement upon notice to Licensee if Licensee becomes insolvent, is adjudged bankrupt, applies for judicial or extra-judicial settlement with its creditors, makes an assignment for the benefit of its creditors, voluntarily files for bankruptcy or has a receiver or trustee (or the like) in bankruptcy appointed by reason of its insolvency, or in the event an involuntary bankruptcy action is filed against Licensee and not dismissed within ninety (90) days, or if the other party becomes the subject of liquidation or dissolution proceedings or otherwise discontinues business.
9.3.Effect of Termination or Expiration.
9.3.1.Termination of Rights.  Upon expiration or termination of this Agreement by either party pursuant to any of the provisions of Section 9.2 the rights and licenses granted to Licensee under Article 2 shall terminate, all rights in and to and under the Patent Rights will revert to Harvard and neither Licensee nor its Affiliates may make any further use or exploitation of the Patent Rights.
9.3.2.Accruing Obligations.  Termination or expiration of this Agreement shall not relieve the parties of obligations accruing prior to such termination or expiration, including obligations to pay amounts accruing hereunder up to the date of termination or expiration.  After the date of termination or expiration (except in the case of termination by Harvard pursuant to Section 9.2), Licensee and its Affiliates (a) may sell Licensed Products then in stock and (b) may complete the production of Licensed Products then in the process of production and sell the same; provided in the case of both (a) and (b) Licensee shall pay the applicable payments to Harvard in accordance with Article 4 and maintain insurance in accordance with the requirements of Section
9.4.Survival.  The parties’ respective rights, obligations and duties under Articles 5, 7 and 8, as well as any rights, obligations and duties which by their nature extend beyond the expiration or termination of this Agreement, shall survive any expiration or termination of this Agreement.
10.Miscellaneous.
10.1.No Security Interest.  Licensee shall not enter into any agreement under which Licensee grants to or otherwise creates in any third party a security interest in this Agreement or any of the rights granted to Licensee herein. Any grant or creation of a security interest purported or attempted to be made in violation of the terms of this Section 10.1 shall be null and void and of no legal effect.
10.2.Use of Name.  Except as provided below, Licensee shall not, and shall ensure that its Affiliates shall not, use or register the name “Harvard” or “HHMI” (alone or as part of another name) or any logos, seals, insignia or other words, names, symbols or devices that identify Harvard or HHMI or any school, unit, division or affiliate of either (“Names”) for any purpose except with the prior written approval of, and in accordance with restrictions required by, Harvard   and/or HHMI, as applicable. Without limiting the foregoing, Licensee shall, and shall ensure that its Affiliates shall, cease all use of Names on the termination or expiration of 
9

this Agreement except as otherwise approved by Harvard  and/or HHMI, as applicable.  This restriction shall not apply to any information required by law to be disclosed.
10.3.Entire Agreement.   This Agreement is the sole agreement with respect to the subject matter hereof and, except as expressly set forth herein, supersedes all other agreements and understandings between the parties with respect to the same.
10.4.Notices.  Unless otherwise specifically provided, all notices required or permitted by this Agreement shall be in writing and may be delivered personally, or may be sent by email, expedited delivery or certified mail, return receipt requested, to the following addresses, unless the parties are subsequently notified of any change of address in accordance with this Section 10.4:
						
	If to Licensee:	Kronos Bio, Inc.
		689 5th Avenue, 12th Floor
		New York, NY 10022
		Email: notice@kronosbio.com
		Attn:
		
	If to Harvard:	Office of Technology Development
		Harvard University
		Richard A. and Susan F. Smith Campus Center, Suite 727
		1350 Massachusetts Avenue
		Cambridge, Massachusetts 02138
		Email: otd@harvard.edu
		Attn.: Chief Technology Development Officer

Any notice shall be deemed to have been received as follows: (a) by personal delivery or expedited delivery, upon receipt; (b) by email, on the date sent; (c) by certified mail, as evidenced by the return receipt.  If notice is sent by email, a confirming copy of the same shall be sent by mail to the same address.
10.5.Governing Law and Jurisdiction.   This Agreement will be governed by, and construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted.  Any action, suit or other proceeding arising under or relating to this Agreement (a “Suit”) shall be brought in a court of competent jurisdiction in the Commonwealth of Massachusetts, and the parties hereby consent to the sole jurisdiction of the state and federal courts sitting in the Commonwealth of Massachusetts. Each party agrees not to raise any objection at any time to the laying or maintaining of the venue of any Suit in any of the specified courts, irrevocably waives any claim that Suit has been brought in any inconvenient forum and further irrevocably waives the right to object, with respect to any Suit, that such court does not have any jurisdiction over such party.
10

10.6.Binding Effect.  This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives, successors and permitted assigns.
10.7.Headings.  Section and subsection headings are inserted for convenience of reference only and do not form a part of this Agreement.
10.8.Counterparts.  The parties may execute this Agreement in two or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.   Transmission by facsimile or electronic mail of an executed counterpart of this Agreement shall be deemed to constitute due and sufficient delivery of such counterpart.  If by electronic mail, the executed Agreement must be delivered in a .pdf format.
10.9.Amendment; Waiver.  This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each party or, in the case of waiver, by the party waiving compliance.  The delay or failure of either party at any time or times to require performance of any provisions hereof shall in no manner affect the rights at a later time to enforce the same.  No waiver by either party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement.
10.10.No Agency or Partnership.  Nothing  contained  in  this  Agreement  shall  give either party the right to bind the other, or be deemed to constitute either party as agent for or partner of the other or any third party.
10.11.Assignment and Successors. This Agreement may not be assigned by either party without the consent of the other, which consent shall not be unreasonably withheld, except that each party may, without such consent, assign this Agreement and the rights, obligations and interests of such party to any of its Affiliates, to any purchaser of all or substantially all of its assets to which the subject matter of this Agreement relates, or to any successor corporation resulting from any merger or consolidation of such party with or into such corporation; provided, in each case, that the assignee agrees in writing to be bound by the terms of this Agreement.   Any assignment purported or attempted to be made in violation of the terms of this Section 10.11 shall be null and void and of no legal effect.
10.12.Force Majeure.  Except for monetary obligations hereunder, neither party will be responsible for delays resulting from causes beyond the reasonable control of such party, including fire, explosion, flood, war, strike, or riot, provided  that the nonperforming party uses commercially reasonable  efforts to avoid or remove  such causes  of nonperformance and continues  performance under this Agreement  with reasonable dispatch whenever  such causes are removed.
10.13.Interpretation.  Each party hereto acknowledges and agrees  that:  (a) it and/or its counsel  reviewed  and negotiated  the terms and provisions of this Agreement  and has contributed to  its  revision;  (b) the  rule of construction to  the effect  that  any ambiguities are 
11

resolved  against the drafting  party shall  not be employed  in the interpretation of this Agreement; (c) the terms and provisions  of this Agreement  shall be construed  fairly as to both parties hereto and not in  favor of or against  either party,  regardless of which party was generally  responsible for the  preparation of this Agreement  and (d) the use of' “include,” “includes,” or “including” herein shall not be limiting and “or” shall not be exclusive.
10.14.Severability.   If any provision of this Agreement  is or becomes  invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the parties  that the remainder of this Agreement shall not be affected.
10.15.HHMI Third  Party  Beneficiary.   HHMI is not a party to this Agreement and has no liability to Licensee or any licensee, sublicensee, or user of anything covered  by this Agreement, but HHMI  is  an intended  third-party  beneficiary  of this  Agreement  and  certain  of its  provisions are for the benefit of HHMI and are enforceable by HHMI in its own name.
IN WITNESS WHEREOF, the parties  have caused this Agreement  to be executed  by their duly authorized representatives as of the date  first written above.
															
	President and Fellows of Harvard College			Kronos Bio, Inc.	
	By:	/s/ Isaac T. Kohlberg		By:	/s/ Christopher M. Wilfong
	Name:	Isaac T. Kohlberg, Senior Associate Provost		Name:	Christopher M. Wilfong
	Title:	Chief Technology Development Officer
Office of Technology Development
Harvard University		Title:	Chief Operating Officer

12

Exhibit 1.4
Patent Rights
[REDACTED]
13THIS
NOTE, IS A GLOBAL SECURITY WITHIN THE MEANING OF SECTION 2.05 OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE
NAME OF THE DEPOSITARY NAMED BELOW OR A NOMINEE OF THE DEPOSITARY. THIS NOTE IS NOT EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME
OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER
OF THIS NOTE (OTHER THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF
THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED
IN THE INDENTURE.

 

UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF CLEARSTREAM BANKING, SOCIÉTÉ ANONYME OR EUROCLEAR
BANK S.A./N.V. (EACH A “DEPOSITARY”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT,
AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF BT GLOBENET NOMINEES LIMITED OR IN SUCH OTHER NAME AS IS REQUESTED BY
AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT IS MADE TO BT GLOBENET NOMINEES LIMITED OR TO SUCH OTHER ENTITY
AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE
BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, BT GLOBENET NOMINEES LIMITED, HAS AN INTEREST HEREIN.

 

THE COCA-COLA COMPANY

 

0.125% Notes
due 2029

 

No.
[__]

€[__________]

 

CUSIP No. 191216 CZ1

ISIN No. XS2233154538

Common Code: 223315453

 

THE
COCA-COLA COMPANY, a Delaware corporation (hereinafter called the “Company,” which term includes any successor corporation
under the Indenture hereinafter referred to), for value received, hereby promises to pay to BT GLOBENET NOMINEES LIMITED (as nominee
of the Depositary), or its registered assigns, the principal sum of [__________] Euros (€[____________])
on March 15, 2029 and to pay interest thereon from September 18, 2020, or from the most recent Interest
Payment Date to which interest has been paid or duly provided for, annually on March 15 in each year, commencing March 15, 2021
at the rate of 0.125% per annum until the principal hereof is paid or made available for payment. Interest on the Securities shall
be computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number
of days from and including the last date on which interest was paid on the Securities (or from September 18, 2020, if no interest
has been paid on the Securities) to but excluding the next scheduled Interest Payment Date. This payment convention is referred
to as ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association. The interest so payable,
and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person
in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record
Date for such interest, which shall be the Business Day immediately preceding such Interest Payment Date. Any such interest which
is payable but is not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular
Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered
at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice
whereof shall be given to Holders of Securities of this Series not less than 10 days prior to such Special Record Date, or be
paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities
of this Series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture.

    	 

    	 

    

As
set forth herein, the Company will pay additional interest on this Security in certain circumstances.

If
either a date for payment of principal or interest on this Security or the Maturity of this Security falls on a day that is not
a Business Day, the related payment of principal or interest will be made on the next succeeding Business Day as if made on the
date the payment was due. No interest will accrue on any amounts payable for the period from and after the date for payment of
principal of or interest on this Security or the Maturity of this Security provided such payment is made on such next succeeding
Business Day. For this purpose, “Business Day” means any day that is not a Saturday or Sunday and that is not a day
on which banking institutions are generally authorized or obligated by law or executive order to close in the City of New York
or London and on which the Trans-European Automated Real-time Gross Settlement Express Transfer system, or any successor thereto,
operates.

Payment
of the principal of and interest on this Security will be made at the office or agency of the Company maintained for that purpose
in a location agreed upon between the Company and the Paying Agent; provided, however, that at the option of the Company payment
of interest, other than interest at Maturity, or upon redemption, may be made by check drawn upon the Paying Agent and mailed-on
or prior to an Interest Payment Date to the address of the Person entitled thereto as such address shall appear in the Securities
Register; provided, further, that (1) the Depositary, as Holder of the Securities, or (2) a Holder of more than €5,000,000
in aggregate principal amount of a Series of Securities in definitive form is entitled to require the Paying Agent to make payments
of interest, other than interest due at Maturity or upon redemption, by wire transfer of immediately available funds into an account
maintained by the Holder in the United States, by sending appropriate wire transfer instructions as long as the Paying Agent receives
the instructions not less than ten days prior to the applicable Interest Payment Date. The principal and interest payable on any
of the Securities at Maturity, or upon redemption, will be paid by wire transfer of immediately available funds against presentation
of a Security at the office of the Transfer Agent and Registrar.

    	 

    	 

    

All
payments on this Security will be payable in Euro. If, however, the Euro is unavailable to the Company due to the imposition of
exchange controls or other circumstances beyond the Company’s control or if the Euro is no longer being used by the then Member
States of the European Monetary Union (the “Member States”) that have adopted the Euro as their currency or for the
settlement of transactions by public institutions of or within the international banking community, then all payments in respect
of this Security will be made in U.S. Dollars until the Euro is again available to the Company or so used. In such circumstance,
the amount otherwise payable by the Company on any date in Euro will be converted into U.S. Dollars at a rate determined by the
Company in good faith. If applicable laws or regulations of the Member States (including official pronouncements applying those
laws or regulations) mandated, in the Company’s good faith determination, the use of a specific exchange rate for these purposes,
the Company will apply the exchange rate so mandated. Any payment in respect of this Security so made in U.S. Dollars will not
constitute an Event of Default under this Security or the Indenture. Neither the Trustee nor the Paying Agent shall have any responsibility
for any calculation or conversion in connection with the foregoing.

Reference
is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for
all purposes have the same effect as if set forth at this place.

Unless
the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof, directly or through
an authenticating agent, by the manual signature of an authorized signatory, this Security shall not be entitled to any benefit
under the Indenture or be valid or obligatory for any purpose.

    	 

    	 

    

IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal.

	Dated:	 	
	 	 	 
	 	THE COCA-COLA COMPANY
	 	 	 
	 	By: 		            
	 		 Name: Christopher P. Nolan
	 		 Title:   Vice President and Treasurer

	Attest:	 	 
	 	 	 
	Name: 	Jennifer Manning	 
	Title:	Secretary	 

    	 

    	 

    

(Trustee’s Certificate
of Authentication)

This is one of the Securities
of the Series provided for in the within-mentioned Indenture.

	 	Deutsche Bank Trust Company Americas, as Trustee
	 	 	 
	 	By:  	 
	 		Authorized Signatory
	 	 	 

    	 

    	 

    

[Reverse]

This
Note (as defined herein) is one of a duly authorized issue of debentures, notes or other evidences of indebtedness of the Company
(herein called the “Securities”), issued and to be issued in one or more Series under an Indenture, dated as of April
26, 1988, as amended and supplemented by that First Supplemental Indenture, dated as of February 24, 1992, and by that Second
Supplemental Indenture, dated as of November 1, 2007 (as so amended and supplemented, herein called the “Indenture”),
between the Company and Bankers Trust Company (now known as Deutsche Bank Trust Company Americas), as Trustee (herein called the
“Trustee”, which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental
thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder
of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated
and delivered. The Securities may be issued in one or more Series, which different Series may be issued in various aggregate principal
amounts, may mature at different times, may bear interest (if any) at different rates, may be denominated and bear interest, if
any, in Dollars or in a Foreign Currency, may be subject to different redemption provisions (if any), may be subject to different
sinking, purchase or analogous funds (if any), may be subject to different covenants and Events of Default and may otherwise vary
as in the Indenture provided. This Security is one of a Series of Securities of the Company designated as set forth on the face
hereof (herein called the “Notes”), limited in aggregate principal amount to €1,000,000,000.

No
sinking fund is provided for the Notes.

In
the event of a deposit or withdrawal of an interest in this Note, including an exchange, redemption or transfer of this Note in
part only, the Trustee or its designee, as custodian of the Depositary, shall make an adjustment on its records to reflect such
deposit or withdrawal in accordance with the rules and procedures of Euroclear and Clearstream applicable to, and as in effect
at the time of, such transaction.

If
an Event of Default with respect to the Notes shall occur and be continuing, the principal of, and accrued interest on, the Notes
may be declared due and payable in the manner and with the effect provided in the Indenture. Upon payment (i) of the amount of
principal so declared due and payable and (ii) of interest on any overdue principal and overdue interest (in each case to the
extent that the payment of such interest shall be legally enforceable), all of the Company’s obligations in respect of the payment
of such principal of and interest, if any, on the Notes shall terminate. The Holders shall have such other rights and remedies
after the occurrence and during the continuance of an Event of Default as set forth in the Indenture.

    	 

    	 

    

The
Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Notes of each Series under the Indenture at any time by the Company and the
Trustee with the consent of the Holders of not less than a majority in aggregate principal amount of the Notes at the time outstanding
of each Series to be affected by such amendment or modification. The Indenture also contains provisions permitting the Holders
of specified percentages in aggregate principal amount of the Notes of each Series at the time outstanding, on behalf of the Holders
of all Notes of such Series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults
under the Indenture and their consequences. Any such consent or waiver by the Holder of this Note shall be conclusive and binding
upon such Holder and upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in
exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note. The Indenture contains
provisions setting forth certain conditions to the institution of proceedings by Holders of Notes with respect to the Indenture
or for any remedy under the Indenture. Section 12.01(a) of the Indenture also contains provisions applicable to the Notes relating
to the Company’s ability to discharge its obligations with respect to the Notes and under the Indenture with respect to the Notes,
upon the deposit of money, German government securities or other government obligations, in an amount sufficient to pay and discharge
the principal of and interest on the Notes to the Maturity of the Note, in certain specified circumstances. The defeasance provisions
described in Section 12.01(b) of the Indenture will not be applicable to the Notes. The lien and sale and lease back provisions
described in Sections 5.03 and 5.04 of the Indenture will not be applicable to the Notes.

Subject
to the next preceding sentence hereof, no reference herein to the Indenture and no provision of this Note or of the Indenture
shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and interest
on this Note at the times, place and rate, and in the coin or currency, herein prescribed.

This
Note is exchangeable for definitive Notes only if (1) the Depositary notifies the Company that it is unwilling or unable to continue
as Depositary for this Note and the Company does not appoint a successor Depositary within 90 days after receiving that notice
or becoming aware that the Depositary is no longer registered or (2) the Company executes and delivers to the Trustee a Company
Order that this Note shall be so exchangeable. In such case, this Note shall be exchangeable into definitive Notes issuable only
in denominations of €100,000 and integral multiples of €1,000 in excess thereof. No definitive Notes shall be issuable
in denominations of less than €100,000. If this Note is exchanged pursuant to the preceding sentences, it shall be exchangeable
for definitive Notes at the office of the Transfer Agent and Registrar, currently located at Deutsche Bank Trust Company Americas,
60 Wall Street, 24th Floor, New York, New York 10005, registered in the name or names that the Depositary gives to
the Trustee, bearing interest at the same rate, having the same date of issuance, redemption provisions, Stated Maturity and other
terms in registered form and of differing denominations aggregating a like amount.

As
provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Note is registrable in the
Securities Register, upon surrender of this Note for registration of transfer at the office or agency of the Transfer Agent and
Registrar, currently located at Deutsche Bank Trust Company Americas, 60 Wall Street, 24th Floor, New York, New York
10005, or at any other office or agency of the Company where the principal of and interest on this Note are payable, duly endorsed,
or accompanied by a written instrument of transfer in form satisfactory to the Company and the Transfer Agent and Registrar, duly
executed, by the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Notes, of authorized
denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

    	 

    	 

    

The
Notes are issuable only in registered form without coupons and only in minimum denominations of €100,000 and any integral
multiple of €1,000 in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth,
this Note is exchangeable for a like aggregate principal amount of Notes of different authorized denominations, as requested by
the Holder surrendering the same.

No
service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient
to cover any tax or other governmental charge payable in connection therewith.

The
Company may redeem the Notes at its option and at any time, either as a whole or in part. If the Company elects to redeem the
Notes, the Company will pay a Redemption Price equal to the greater of:

		·	100% of the principal amount
of the Notes to be redeemed, plus accrued and unpaid interest; and

		·	the sum of the present values
of the Remaining Scheduled Payments, plus accrued and unpaid interest (excluding any portion of such payments of interest accrued
as of the Redemption Date).

In
determining the present value of the Remaining Scheduled Payments, the Company will discount such payments to the Redemption Date
on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate, plus 15 basis points. A partial redemption
of the Notes may be effected by such method as the Paying Agent shall deem fair and appropriate in accordance with Clearstream/Euroclear’s
procedures and may provide for the selection for redemption of portions (equal to the minimum authorized denomination for the
Notes or any integral multiple of €1,000 in excess thereof) of the principal amount of Notes of a denomination larger than
the minimum authorized denomination for the Notes.

The
term “Comparable Government Bond Rate” means the yield to maturity, expressed as a percentage (rounded to three decimal
places, with 0.0005 being rounded upwards), on the third Business Day prior to the Redemption Date, of the Comparable Government
Bond (as defined below) on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00 a.m. (London
time) on such Business Day as determined by an independent investment bank selected by the Company.

The
term “Comparable Government Bond” means, with respect to any Redemption Date, in relation to any Comparable Government
Bond Rate calculation, at the discretion of an independent investment bank selected by the Company, the 0.250% German Bundesobligationen
due February 15, 2029, or if such independent investment bank in its discretion determines that such bond is not in issue, such
other German Bundesobligationen as such independent investment bank may, with the advice of three brokers of, and/or market makers
in, German government bonds selected by the Company, determine to be appropriate for determining the Comparable Government Bond
Rate.

    	 

    	 

    

The
term “Remaining Scheduled Payments” means, with respect to any Note, the remaining scheduled payments of the principal
thereof to be redeemed and interest thereon that would be due after the related Redemption Date but for such redemption; provided,
however, that, if such Redemption Date is not an Interest Payment Date with respect to such Note, the amount of the next scheduled
interest payment thereon will be reduced by the amount of interest accrued thereon to such Redemption Date.

Notice
of any redemption will be mailed at least 15 days but not more than 30 days before the Redemption Date to each holder of Notes
to be redeemed.

Unless
the Company defaults in payment of the Redemption Price, on and after the Redemption Date interest will cease to accrue on the
Notes or portions thereof called for redemption. Neither the Trustee nor the Paying Agent shall be responsible for calculation
of the Redemption Price.

The
Company will, subject to the exceptions and limitations set forth below, pay as additional interest on the Notes such additional
amounts as are necessary in order that the net payment by the Company of the principal of and interest on the Notes to a Holder
who is not a United States Person (as defined below), after withholding or deduction for any present or future tax, assessment
or other governmental charge imposed by the United States or a taxing authority in the United States, will not be less than the
amount provided in the Notes to be then due and payable; provided, however, that the foregoing obligation to pay additional amounts
shall not apply:

		(1)	to any tax, assessment or
other governmental charge that is imposed by reason of the Holder (or the beneficial owner for whose benefit such Holder holds
such Note), or a fiduciary, settlor, beneficiary, member or shareholder of the Holder if the Holder is an estate, trust, partnership
or corporation, or a Person holding a power over an estate or trust administered by a fiduciary holder, being considered as:

 (a) being or having been engaged in a trade or business in the United States or having or having had a permanent establishment in the United States;

 

 (b) having a current or former connection with the United States (other than a connection arising solely as a result of the ownership of the Notes or the receipt of any payment or the enforcement of any rights thereunder), including being or having been a citizen or resident of the United States;

 

 (c) being or having been a personal holding company, a passive foreign investment company or a controlled foreign corporation for United States income tax purposes or a corporation that has accumulated earnings to avoid United States federal income tax;

    	 

    	 

    
 (d) being a controlled foreign corporation within the meaning of Section 957(a) of the United States Internal Revenue Code of 1986, as amended (the “Code”) related within the meaning of Code Section 864(d)(4) to the Company;

 

(e) being or having been a “10-percent shareholder” of the Company as defined in section 871(h)(3) of the Code, or any successor provision;

 

(f) being subject to income tax withholding or backup withholding as of the date of the purchase by the Holder or beneficial owner of the Notes; or

  

(g) being a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business;

 

	(2)	to any Holder that
    is not the sole beneficial owner of the Notes, or a portion of the Notes, or that is a fiduciary, partnership or limited liability
    company, but only to the extent that a beneficial owner with respect to the Holder, a beneficiary or settlor with respect
    to the fiduciary, or a beneficial owner or member of the partnership or limited liability company would not have been entitled
    to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial
    or distributive share of the payment;

	(3)	to any tax, duty,
    levy, assessment or other governmental charge which would not have been imposed but for the presentation of the note or evidence
    of beneficial ownership thereof (where presentation is required) for payment on a date more than 30 days after the date on
    which such payment becomes due and payable or the date on which payment is duly provided for, whichever occurs later;

	(4)	to any tax, assessment
    or other governmental charge that would not have been imposed but for the failure of the Holder or any other Person to comply
    with certification, identification or information reporting requirements concerning the nationality, residence, identity or
    connection with the United States of the Holder or beneficial owner of the Notes, if compliance is required by statute, by
    regulation of the United States or any taxing authority therein or by an applicable income tax treaty to which the United
    States is a party as a precondition to exemption from such tax, assessment or other governmental charge;

	(5)	to any inheritance,
    gift, estate, personal property, sales, transfer or similar tax, duty levy, assessment, or similar governmental charge;

	(6)	to any tax, duty,
    levy, assessment, or other governmental charge that is payable otherwise than by withholding from payments in respect of the
    Notes;

	(7)	to any tax, duty,
    levy, assessment or governmental charge that would not have been imposed but for an election by the Holder or beneficial owner
    of the Notes, the effect of which is to make one or more payments in respect of the Notes subject to United States federal
    income tax, state or local tax, or any other tax, duty, levy, assessment or other governmental charge;

	(8)	to any tax, duty,
    levy, assessment or governmental charge imposed under any of Sections 1471 through 1474 of the Code, any applicable United
    States Treasury Regulations promulgated thereunder, or any judicial or administrative interpretation of any of the foregoing;
    or

	(9)	to any combination
    of items (1), (2), (3), (4), (5), (6), (7), or (8) above.

    	 

    	 

    

This
Note is subject in all cases to any tax, fiscal or other law or regulation or administrative or judicial interpretation applicable
to this Note. Except as specifically provided above, no payment will be required for any tax, assessment or other governmental
charge imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.

If
the Company is required to pay any additional amounts as described above with respect to the Notes, the Company will notify the
Trustee and the Paying Agent pursuant to an Officer’s Certificate that specifies the additional amounts payable and when
the additional amounts are payable. If the Trustee and the Paying Agent do not receive such an Officer’s Certificate from
the Company, the Trustee and the Paying Agent may rely on the absence of such an Officer’s Certificate in assuming that
no such additional amounts are payable.

The
term “United States” means the United States of America, the states of the United States, and the District of Columbia,
and the term “United States Person” means any individual who is a citizen or resident of the United States for United
States federal income tax purposes, a corporation, partnership or other entity created or organized in or under the laws of the
United States, any state of the United States or the District of Columbia, or any estate or trust the income of which is subject
to United States federal income taxation regardless of its source.

If,
as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United
States (or any taxing authority in the United States), or any change in, or amendment to, an official position regarding the application
or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after
September 14, 2020, the Company becomes or, based upon a written opinion of independent counsel selected by the Company, will
become obligated to pay additional amounts as described above with respect to the Notes, then the Company may at any time at the
Company’s option redeem, in whole, but not in part, the Notes on not less than 15 nor more than 30 days’ prior notice
to the Holders, at a redemption price equal to 100% of their principal amount plus accrued and unpaid interest on the Notes to
the Redemption Date.

The
Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Note is registered as
the owner hereof for all purposes, whether or not this Note is overdue, and neither the Company, the Trustee nor any such agent
shall be affected by notice to the contrary.

All
terms used in this Note which are defined in the Indenture shall have the meanings assigned to them in the Indenture. The Notes
are governed by the laws of the State of New York.

    	 

    	 

    

ABBREVIATIONS

The following
abbreviations, when used in the inscription of the face of this Note, shall be construed as though they were written out in full
according to applicable laws or regulations:

	TEN
    COM	-	as
    tenants in common
	TEN
    ENT	-	as
    tenants by entireties (Cust)
	JT
    TEN	-	As
    joint tenants with right of survivorship and not as tenants in common
	UNIF
    GIFT MIN ACT	-	_____________ Custodian __________________

                                                                  (Minor)

        Under Uniform Gifts to Minors Act ________________

                                                                              (State)

Additional abbreviations
may also be used though not in the above list.

    	 

    	 

    

FORM OF ASSIGNMENT

 

For value received  _____________ hereby
sell(s), assign(s) and transfer(s) unto _______________ (Please insert social security or other identifying number of assignee)
the within Note, and hereby irrevocably constitutes and appoints __________________________  as attorney to transfer the said Note
on the books of the Company, with full power of substitution in the premises.

	Dated:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	Signature(s)
		 	 
	 	 	Signature(s) must be guaranteed by an Eligible Guarantor Institution with membership in an approved signature guarantee program pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]